Halozyme Therapeutics (HALO) Change in Acquisitions & Divestments (2013 - 2026)

Halozyme Therapeutics (HALO) has 14 years of Change in Acquisitions & Divestments data on file, last reported at $9.0 million in Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments fell 82.06% year-over-year to $9.0 million in Q1 2026; TTM through Mar 2026 was $681.1 million, a 108.85% increase from a year earlier, with the FY2025 full-year figure at $722.2 million, up 82.58% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $9.0 million, down from $273.4 million in the prior quarter.
• Over the last five years, Change in Acquisitions & Divestments for HALO reached as high as $590.0 million in Q2 2022 and fell as low as $9.0 million in Q1 2026.
• Historically, Change in Acquisitions & Divestments has averaged $130.3 million across 5 years, with a median of $82.6 million in 2023.
• Across the five-year window, Change in Acquisitions & Divestments soared 667.59% in 2022 and tumbled 90.95% in 2023, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $20.1 million in 2022, then decreased by 22.52% to $15.6 million in 2023, then surged by 438.34% to $84.0 million in 2024, then surged by 225.54% to $273.4 million in 2025, then tumbled by 96.71% to $9.0 million in 2026.
• Per Business Quant data, the three most recent Change in Acquisitions & Divestments figures were $9.0 million in Q1 2026, $273.4 million in Q4 2025, and $209.6 million in Q3 2025.